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Summary
Background—The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire 
Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but 
duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in 
volunteers who received single-dose rVSV-ZEBOV in three previous trials.
Methods—In this observational cohort study, we prospectively followed-up participants from the 
African and European phase 1 rVSV-ZEBOV trials, who were vaccinated once in 2014–15 with 
300 000 (low dose) or 10–50 million (high dose) plaque-forming units (pfu) of rVSV-ZEBOV 
vaccine to assess ZEBOV glycoprotein (IgG) antibody persistence. The primary outcome was 
ZEBOV glycoprotein-specific IgG geometric mean concentrations (GMCs) measured yearly by 
ELISA compared with 1 month (ie, 28 days) after immunisation. We report GMCs up to 2 years 
(Geneva, Switzerland, including neutralising antibodies up to 6 months) and 1 year (Lambaréné, 
Gabon; Kilifi, Kenya) after vaccination and factors associated with higher antibody persistence 
beyond 6 months, according to multivariable analyses. Trials and the observational study were 
registered at ClinicalTrials.gov (Geneva: NCT02287480 and NCT02933931; Kilifi: 
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NCT02296983) and the Pan-African Clinical Trials Registry (Lambaréné 
PACTR201411000919191).
Findings—Of 217 vaccinees from the original studies (102 from the Geneva study, 75 from the 
Lambaréné study, and 40 from the Kilifi study), 197 returned and provided samples at 1 year (95 
from the Geneva study, 63 from the Lambaréné, and 39 from the Kilifi study) and 90 at 2 years (all 
from the Geneva study). In the Geneva group, 44 (100%) of 44 participants who had been given a 
high dose (ie, 10–50 million pfu) of vaccine and who were seropositive at day 28 remained 
seropositive at 2 years, whereas 33 (89%) of 37 who had been given the low dose (ie, 300 000 pfu) 
remained seropositive for 2 years (p=0·042). In participants who had received a high dose, 
ZEBOV glycoprotein IgG GMCs decreased significantly between their peak (at 1–3 months) and 
month 6 after vaccination in Geneva (p<0·0001) and Lambaréné (p=0·0298) but not in Kilifi 
(p=0·5833) and subsequently remained stable at all sites apart from Geneva, where GMC in those 
given a high dose of vaccine increased significantly between 6 months and 1 year (p=0·0264). 
Antibody persistence was similar at 1 year and at 6 months in those who had received a low dose 
of vaccine, with lower titres among participants from the Geneva study at 2 years than at 1 year 
after vaccination (GMC ratio 0·61, 95% CI 0·49–0·77; p<0·0001). In multivariable analyses, 
predictors of increased IgG GMCs beyond 6 months included high-dose versus low-dose 
vaccination (Geneva p=0·0133; Lambaréné p=0·008) and vaccine-related arthritis (p=0·0176), but 
not sex, age, or baseline seropositivity (all p>0·05). Neutralising antibodies seem to be less 
durable, with seropositivity dropping from 64–71% at 28 days to 27–31% at 6 months in 
participants from the Geneva study.
Interpretation—Antibody responses to single-dose rVSV-ZEBOV vaccination are sustained 
across dose ranges and settings, a key criterion in countries where booster vaccinations would be 
impractical.
Funding—The Wellcome Trust and Innovative Medicines Initiative 2 Joint Undertaking.
Introduction
The live-attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing the 
glycoprotein of Zaire Ebola virus (ZEBOV) has been granted Breakthrough Therapy 
Designation status by the US Food and Drug Administration and Priority Medicine 
(PRIME) status by the European Medicines Agency after it was found to be highly 
immunogenic for 12 months1–3 and efficacious up to 12 weeks following single-dose 
injection.4 The long-term durability of immune responses to this single injection and 
protection over longer periods in areas that are endemic for Ebola virus disease are yet 
undefined. The durability of the vaccine response becomes increasingly important as more 
outbreaks occur5 and more information is collected on the persistence of Ebola virus itself 
within human hosts—eg, replication-competent Ebola viruses have been isolated from 
patient samples collected up to 9 months after initial Ebola virus disease,6 and viral RNA 
has been detected up to 2 years after initial infection.7 Indeed, the Wellcome Trust–Center 
for Infectious Disease Research and Policy Ebola Vaccine Team B initiative8 recommends 
that any vaccine for the immunisation of disease contacts (ie, anyone who has had any 
contact with a person who had the disease) should induce protection that lasts at least 2 
years. This goal is challenging and has not yet been reported for rVSV-ZEBOV vaccine (also 
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known as rVSVΔG-EBOV-GP). For example, antibody titres to ZEBOV glycoprotein had 
dropped in all participants at 6 months after a single dose of the recombinant, non-
replicating chimpanzee adenovirus 3 (rChAd3)-ZEBOV vaccine.9
Despite the effectiveness of the rVSV-ZEBOV vaccine in the field,4 trends of vaccine-
induced protection against Ebola virus disease remain undefined. The WHO-sponsored 
Guinea ring vaccination trial4 documenting field efficacy did not harvest blood for 
immunogenicity analyses, and the mechanisms conferring protection in non-human primate 
models have not been confirmed to be the same in man.10 Although the identification of 
immune mediators is only at an early phase, passive antibody transfer protects naive non-
human primates against lethal Ebola virus,11 and such antibodies are required for 
protection.12 In human beings, rVSV-ZEBOV-induced antibodies that are likely to 
contribute to protection include neutralising and non-neutralising antibodies to the ZEBOV 
glycoprotein.13–15 Thus the presumed durability of rVSV-ZEBOV-induced protection 
might be best estimated by antibody persistence in people who have been given the vaccine.
Beginning in November, 2014, the VSV-Ebola Consortium (VEBCON)1 did a large (115 
participants) phase 1/2 randomised, placebo-controlled trial in Geneva, Switzerland,1,2,16 
with parallel dose-escalation trials in Hamburg, Germany (30 participants), Lambaréné, 
Gabon (75 participants), and Kilifi, Kenya (40 participants).1 Early immunogenicity results 
of these investigator-initiated trials have been reported.1,2 The Lambaréné trial’s follow-up 
phase was extended, and participants who received the vaccine from the Geneva trial were 
invited to participate in a prospective observational study to establish antibody persistence. 
Here we present persistence data at 1 year for participants who were vaccinated in the 
Lambaréné, Kilifi, and Geneva studies and at 2 years for the Geneva study. We further 
explore factors associated with sustained or waning antibody concentrations.
Methods
Study designs and participants
The phase 1 trials that recruited healthy volunteers from the community in Geneva, 
Switzerland, Lambaréné, Gabon, Kilifi, Kenya, and Hamburg, Germany, launched in 2014–
15 and have been described extensively elsewhere (for inclusion and exclusion criteria see 
ClinicalTrials.gov [NCT02287480 and NCT02296983] and Pan African Trials Registry 
[PACTR201411000919191]).1,2 We invited participants who had received the vaccine in the 
Geneva, Lambaréné, and Kilifi studies, to participate in this observational cohort study; the 
Hamburg study had already terminated at 6 months after vaccination and so participants 
were not recruited from this trial. Although the Geneva and Kilifi phase 1 trials terminated 
after 12 months of follow-up, the follow-up phase of the Lambaréné trial was extended to 4 
years after intial vaccination, and volunteers from the Geneva study were invited to 
participate in a 4-year prospective observational study (NCT02933931). We report here 
antibody concentrations at 1 and 2 years after immunisation, from members of the follow-up 
population when available, compared with early (28 days after rVSV-ZEBOV vaccination) 
results to define persistence or waning.
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In the Geneva study, all adults who both participated in the phase 1 trial and received a 
single dose of either 300 000, 10 million, or 50 million plaque-forming units (pfu) of rVSV-
ZEBOV vaccine according to protocol were eligible for follow-up in this observational 
study. Since the randomised Geneva phase 1 trial had revealed no differences in 
reactogenicity, viraemia, or early immunogenicity after vaccination with 10 million or 50 
million pfu of vaccine,1,2 volunteers from the study receiving these doses were again 
grouped as high-dose participants, whereas those who had received 300 000 pfu of vaccine 
were grouped as low-dose participants.
The follow-up population consisted of volunteers from the three sites who adhered to the 
studies’ protocols (eg, did not undergo further rVSV-ZEBOV vaccination) and who had no 
suspected or documented clinical exposure to Ebola virus throughout the study period (ie, 
from vaccination to end of follow-up). A detailed description of the Geneva, Lambaréné, and 
Kilifi cohorts is provided in the appendix.
All phase 1 trials received ethics approval from WHO’s Ethics Committee and from their 
local and regional ethics committees (for the Geneva study: the Geneva Cantonal Ethics 
Commission; for the Lambaréné study: the Institutional Ethics Committee of the Centre de 
Recherche Médicales de Lambaréné; and for the Kilifi study: the National Ethics Committee 
of Gabon, the Institutional Ethics Committee of the Universitätsklinikum Tübingen, and the 
Kilifi Ethics Committee). The follow-up observational study in Geneva received additional 
ethics approval from the Geneva Cantonal Ethics Commission (approval no. 2016-00918).
All Geneva volunteers provided written informed consent before enrolment in this follow-up 
observational study. The Kilifi and Lambaréné volunteers had given written informed 
consent to be included in their respective original trials.
Procedures
Serum samples from all studies were frozen at −20°C before transfer to the Non-Clinical 
Development laboratory at the US Army Medical Research Institute for Infectious Diseases 
(USAMRIID), Fort Detrick, MD, USA. ZEBOV glycoprotein-specific antibodies were 
quantified with the Filovirus Animal Non-Clinical Group (FANG)-approved ELISA by use 
of the homologous Zaire-Kikwit strain glycoprotein, following USAMRIID’s standard 
operating procedure (SOP AP-03–35; USAMRIID ELISA).1 To improve interassay 
comparisons, the relative amounts oxOV glycoprotein-specific antibodies previously 
reported as endpoint titres1,2 were recalculated as arbitrary ELISA units per mL (EU/mL) 
compared with a reference standard. To convert from EU/mL to IU/mL, EU/mL is divided 
by 27 135·90. The mean optical density for cutoff values of negative samples was 0·218 
EU/mL (SD 0·0321). By solving x when y=0·218 for each of the four parameter logistic 
regression curves, using seven Human Reference Standards, we found that the lower limit of 
quantification was 48·7 EU/mL (SD 5·07). Values were log10-transformed and reported as 
geometric mean concentrations (GMCs) in arbitrary EU/mL with 95% CIs, as indicated. 
Samples were taken at 0, 28, 84, 168, 365, and 730 days in the Geneva group, 0, 28, 56, 84, 
180, and 365 days in the Lambaréné group, and 0, 30, 60, 90, 180, and 365 days in the Kilifi 
group. For the purposes of this analysis, we refer to measurements taken at 168 and 180 days 
as 6-month measurements. Neutralising antibodies were assessed in serum samples that 
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were harvested from volunteers from the Geneva study at baseline (before vaccination), day 
28, and month 6 (appendix).
Outcomes
Unless protection only requires very low antibody concentrations, persistence of 
seropositivity is an unlikely correlate of protection. However, assuming IgG measured by 
ELISA was a marker of immunity, maintenance of the GMCs seen at day 28, at which point 
a high dose of rVSV-ZEBOV vaccine (20 million pfu) was effective in a ring vaccination 
setting,4 could be indicative of protection. The main outcome in this observational study was 
ZEBOV glycoprotein-specific GMC measured by ELISA at yearly timepoints, compared 
with GMCs measured at 28 days. Other endpoints were seropositivity at 1 and 2 years; 
seropositivity persistence at 1 and 2 years compared with day 28; the geometric mean fold 
increase between two timepoints (eg, 6 months and 1 year); GMCs of neutralising antibody 
titres in the Geneva group at baseline and on days 28 and 168; the association between 1-
year GMCs of ZEBOV glycoprotein-specific antibodies and baseline characteristics (eg, sex, 
age, and baseline seropositivity); and the correlation between vaccine-related arthritis, GMC 
status, and dose of vaccine. Seropositivity was experimentally defined by adding two SDs to 
the mean of negative samples, defining a seropositivity threshold of 58·84 EU/mL or higher. 
In the absence of established correlates of protection, antibody persistence was defined by 
the maintenance of seropositivity or the ratio of anti-ZEBOV IgG GMCs at a given follow-
up timepoint compared with day 28, or both. Seroconversion occurred when a previously 
negative sample reached a concentration equal to or greater than 58·84 EU/mL. For 
neutralising antibodies, a titre of 1:8 or higher was experimentally defined as seropositive 
(appendix).
Statistical analysis
The sample size of the three follow-up cohorts was not calculated but predetermined by the 
number of participants who fulfilled the defined eligibility criteria and provided serum 
samples at a given timepoint.
We calculated GMCs of ZEBOV glycoprotein-specific IgG antibodies and 95% CIs for all 
volunteers with available data using a log10 transformation. Given the USAMRIID ELISA’s 
limit of seropositivity of 58·84 EU/mL, we arbitrarily assigned titres below this value a 
lower value of 29·42 EU/mL (half the limit of seropositivity) for statistical analyses. We 
report seropositivity with Clopper-Pearson’s 95% CIs. We did comparisons of GMCs and 
seropositivity between independent groups using t test and Fisher’s exact test. We did 
comparisons of GMCs and seropositivity between two timepoints using t test for paired data 
and McNemar’s test. We assessed geometric mean fold increases between two timepoints. 
We investigated associations between GMCs at 1 year after vaccination and baseline 
demographic factors (sex, age) by comparing GMCs between subgroups or by assessing 
Spearman’s correlation coefficients. We applied a linear regression model to test whether the 
magnitude of the association between vaccine-related arthritis and GMC 2 years after 
vaccination was the same in volunteers from the Geneva study who were given a low dose of 
vaccine and those who were given a high dose. We applied linear regression models with 
mixed effects to investigate ZEBOV-IgG antibody persistence, accounting for repeated 
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measures of ELISA titre and adjusting for sex, age, baseline seropositivity, and vaccine-
related arthritis. A detailed description of statistical methods we used can be found in the 
appendix. All analyses were done by the R Development Core Team, 2008 (R Foundation 
for Statistical Computing, Vienna, Austria). The trials and the observational study were 
registered at ClinicalTrials.gov (Geneva NCT02287480 and NCT02933931; Kilifi 
NCT02296983) and the Pan-African Clinical Trials Registry (Lambaréné 
PACTR201411000919191).
Role of the funding source
The funders of the phase 1 trials (Wellcome Trust Foundation) and the follow-up 
observational study (Innovative Medicines Initiative) had no role in the study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all study data and had final responsibility for the decision to submit 
for publication.
Results
Between vaccination during the period November, 2014, to January, 2015, and 1-year 
follow-up for the Lambaréné and Kilifi groups in the period November, 2015, to January, 
2016, or 2-year follow-up for the Geneva group in the period November, 2016, to January, 
2017, the 230 participants in the previous phase 1/2 trials on rVSV-ZEBOV vaccination in 
Geneva (115 participants), Lambaréné (75 participants), and Kilifi (40 participants) were 
assessed, and 214 were eligible to participate in the observational study (99 from the Geneva 
study [102 had been vaccinated; however, three were not eligible for invitation to this 
observational study; one had had another vaccination, and two were lost to follow-up], 75 
from the Lambaréné study, and 40 from the Kilifi study). 197 attended the 1-year follow-up, 
95 (96%) from the Geneva study, 63 (84%) from the Lambaréné study, and 39 (98%) from 
the Kilifi study, and, for the Geneva study population, 90 (91%) attended the 2-year follow-
up (figure 1). All demographic, clinical, and immunological characteristics of volunteers 
attending the 1-year after vaccination visit are in table 1.
For the Geneva study population, at the 1-year visit, 49 (52%) of 95 attendees had been 
given the low dose of vaccine (ie, 300 000 pfu), and 46 (48%) had been given a high dose of 
vaccine (10–50 million pfu). Most participants (92 [97%]) had been seronegative before 
vaccination (table 1); at the 2-year visit, 45 volunteers who had been given a low dose of 
vaccine and 45 volunteers who had been given a high dose of vaccine returned; baseline 
seronegativity remained 97%. Among the 75 Lambaréné phase 1 participants, 63 returned 
for the 1-year follow-up: 15 (24%) had been given 300 000 pfu of vaccine, 36 (57%) had 
been given 3 million pfu, and 12 (19%) had been given 20 million pfu. Baseline 
seropositivity in this group 1 year after vaccination was much higher (14 [22%] of 63) in this 
Ebola virus disease-endemic area than in the Geneva or Kilifi groups. In the Kilifi phase 1 
trial population, 39 (98%) of 40 attended the 1-year follow-up; only one (3%) of 39 
attendees had been seropositive at baseline (table 1).
In the Geneva group, 45 (100%) of 45 volunteers who were given the high-dose vaccine and 
completed 1-year follow-up (and had day-28 data) were seropositive on day 28, compared 
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with 39 (80%) of 49 given the low-dose vaccine (p=0·001). In the Lambaréné group, all (48 
[100%] volunteers who were given 3 million pfu or more of vaccine were seropositive on 
day 28 compared with 13 (87%) of 15 who were given the lower dose of 300 000 pfu of 
vaccine (p=0·079). In the Kilifi group, all participants had been given 3 million or 20 million 
pfu of vaccine and they were all seropositive by day 28. Thus, vaccine dose influenced early 
(ie, day 28) antibody responses, as described previously by us1,2 and others.3
In the absence of established correlates of protection, seropositivity persistence was taken as 
a first, low-stringency marker for the persistence of vaccine-induced responses. 
Seropositivity at 1 year at all sites and 2 years after vaccination in the Geneva group did not 
differ significantly among dose groups (appendix). In volunteers who had been given 3 
million pfu or more of vaccine, seropositivity persisted (45 [100%] of 45 volunteers in the 
Geneva group at 2 years, 48 [100%] of 48 in the Lambaréné group at 1 year, and 39 [100%] 
of 39 tested [one volunteer was not tested] in the Kilifi group at 1 year). Delayed 
seropositivity responses were occasionally seen in volunteers who had been given 300 000 
pfu of vaccine, with 39 (80%) of 49 volunteers in the Geneva study seropositive at 1 year 
and 41 (91%) of 45 seropositive at 2 years; and 17 (85%) of 20 volunteers in the Lambaréné 
group seropositive at day 28 and 15 (100%) of 15 seropositive at 1 year (p=0·244; 
appendix). Thus, 1 year and 2 years after vaccination seropositivity remained high and dose 
dependency was lost.
In the Geneva group, 44 (100%) of 44 participants who had been given a high dose (ie, 10–
50 million pfu) of vaccine and who were seropositive at day 28 remained seropositive at 2 
years, whereas 33 (89%) of 37 who had been given the low dose (ie, 300 000 pfu) of vaccine 
and who were seropositive at day 28 remained seropositive for 2 years (p=0·042). Further 
details of the similarly high proportions of participants with seropositivity persistence in the 
Lambaréné and Kilifi groups are shown in the appendix.
Figure 2 shows and table 2 lists GMCs of rVSV-ZEBOV glycoprotein-specific antibodies for 
each dose group at each site over time, and GMC ratios across each timepoint in each group 
are shown in the appendix. GMCs peaked between 1 and 3 months after vaccination in all 
dose groups, although this finding was less pronounced in the Kilifi group. Baseline 
seropositivity, frequent in Lambaréné, did not influence follow-up GMCs compared with 
seronegative volunteers receiving the same dose, at this site or in Geneva or Kilifi (table 3). 
In all sites and across all doses, GMC peaks were followed by an initial decline until month 
6 (table 3). GMCs then plateaued between 6 and 12 months across doses and settings, and 
up to 2 years in participants who had been given a high dose of vaccine in the Geneva group 
(table 3). In the Geneva group, lower 2-year titres than 1-year titres were seen in participants 
who were given the low dose of vaccine (GMC ratio 0·61, 95% CI 0·49–0·77; p<0·0001).
Because comparing GMCs could mask antibody disappearance in a subset of participants, 
individual values are given at each timepoint in the appendix; this analysis shows that the 
lower GMCs at day 28 in people who were given the low dose of vaccine (300 000 pfu) are 
due to a slow response in some volunteers to this low dose, whereas higher doses (≥3 million 
pfu) induce a more prompt and stronger response. Furthermore, complete antibody loss was 
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rare after 6 months, and was only observed in four (9%) of 45 participants given the low 
dose.
For the Geneva group, neutralising antibody geometric mean titres assessed at baseline, day 
28, and at month 6 with Ebola virus are shown in the appendix. The proportion of 
participants with seropositivity increased from zero at baseline to 71% (ten of 14 
participants who received 50 million pfu) on day 28. By month 6, titres had fallen to low 
levels in all dose groups, with seropositivity dropping to 27–31%.
Univariable analyses detected higher GMCs of ZEBOV glycoprotein-specific antibodies at 1 
year in female participants than in male participants who received a high dose in the Geneva 
group (appendix), although in multivariable models significance was not reached (table 3). 
Similarly, although univariable analyses detected an association between increasing age and 
increased GMCs in participants who received the low dose in the Geneva group (appendix), 
a multivariable regression model with mixed effects and adjusted for sex, age, and 
seropositivity at baseline indicates that GMC ratios were influenced by whether the 
participant was given a high dose versus a low dose of vaccine in Geneva (1·66, 95% CI 
1·12–2·46; p=0·0133) and Lambaréné (2·56, 1·30–5·03; p=0·008; appendix). GMC ratios 
were not influenced by sex, age, or baseline seropositivity (table 3).
In the Geneva group, 13 (25%) of 51 people who were given the low dose of vaccine and 11 
(22%) of 51 who were given the high dose of vaccine reported vaccine-related arthritis at a 
median of 10 days (IQR 9–14) after immunisation.1,2 In the 6 months following 
vaccination, two participants with early vaccine-related arthritis had suspected, self-limited 
recurrences of arthritis.1 Since then, no episodes were reported up until March 22, 2018. 
However, the occurrence of vaccine-related arthritis after vaccination was associated with 
increased ZEBOV glycoprotein-specific IgG GMCs throughout the 2-year follow-up period 
(figure 3). The association was only significant in the low-dose group; anti-ZEBOV GMCs 
of participants with vaccine-related arthritis were significantly higher than those without 
vaccine-related arthritis at every timepoint (p<0·05 for all), and by 2 years after vaccination, 
the anti-ZEBOV GMCs of participants with vaccine-related arthritis were higher than those 
of participants who received a high dose who did not have vaccine-related arthritis (1270·1 
EU/mL, 95% CI 612·4–2634·2 vs 659·5 EU/mL, 467·3–931·0; p=0·5189; figure 3; 
appendix). Volunteers who had been given the high dose of vaccine who had vaccine-related 
arthritis also achieved higher GMCs than those who did not get vaccine-related arthritis, but 
the difference did not reach significance (appendix). A multivariable linear regression model 
to investigate interactions between vaccine dose and vaccine-related arthritis did not reveal 
an influence of the dose on the GMC ratios and 2-year titres of those with and those without 
vaccine-induced arthritis (pinteraction=0·596; appendix). The multivariable regression model 
with mixed effects confirmed the association of arthritis with increased antibody persistence 
when adjusting for sex, age, and baseline seropositivity (table 3). The occurrence of vaccine-
related arthritis did have a significant effect on GMC when participants who received low 
doses and high doses of vaccine were combined in the Geneva group (GMC ratio 1·76, 95% 
CI 1·11–2·78; p=0·0176; appendix).
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Discussion
The humoral response induced by a single injection of the replication-competent rVSV-
ZEBOV vaccine persisted for at least 1–2 years across three populations in two different 
continents and with different doses, with kinetics enabling the prediction of long-term 
antibody persistence in most people who were given the vaccine. The data from the Geneva 
group show that 100% of early responders given 10 million pfu or more of vaccine remained 
seropositive at 2 years after vaccination, with similar patterns seen in two African countries 
(Lambaréné, Gabon, and Kilifi, Kenya). Even at the lowest dose of 300 000 pfu, 89% of 
participants with seroconversion remained seropositive 2 years after vaccination. Thus, a 
single injection of rVZV-ZEBOV induced sustained antibody responses in almost all 
participants who were given the vaccine.
The kinetics of ZEBOV glycoprotein-specific IgG antibodies were typical of other live-
attenuated vaccines. After an early peak at 2–3 months after the single-dose vaccination, 
during which ZEBOV glycoprotein-specific antibodies were most likely produced by short-
lived plasmablasts,17 antibody concentrations followed an initial decline, with no significant 
subsequent decreases in GMCs between 28 days and up to 1 or 2 years after vaccination, or 
6 months and up to 1 or 2 years after vaccination. In the absence of exposure to filoviruses 
after immunisation (in the Geneva or Kilifi groups) that could have boosted vaccine 
responses, this result probably reflects an effective switch from short-lived to long-lived 
plasma cells following rVSV-ZEBOV immunisation17 and provides an immunological basis 
for long-lasting protection, should the protection be mediated by vaccine antibodies. 
Multivariable analyses indicating a decline in 2-year GMCs in participants who were given 
the low dose of vaccine (but not those who were given the high dose) in the Geneva group 
warrant further follow-up.
Protective humoral responses to natural viral infections can be extremely sustained, even 
lifelong. Circulating, antigen-specific antibodies have been detected in patients with no 
interim exposure for as long as 65 years for measles infection and 75 years for yellow fever 
infection.18,19 Some live-attenuated vaccines appear to induce similar lifelong humoral 
immunity—eg, antigen-specific IgG concentrations have been consistent for several decades 
after single-dose injection with the smallpox20 and yellow fever21 vaccines in patients 
without pathogen exposure. The results from this observational study allow some degree of 
cautious optimism regarding the long-term persistence of antibody responses and of 
protection should vaccine antibodies confer protection. The heavily glycosylated 
glycoprotein of Ebola virus behaves as a rather weak immunogen, at least when presented in 
some vaccine formulations, as shown by the rapid disappearance of glycoprotein-specific 
antibodies following a single dose of the glycoprotein delivered by the non-replicating 
(single-cycle) rChAd3 vector vaccine.9 Therefore, we presume that the sustainability of 
humoral responses to rVSV-ZEBOV vaccine essentially results from the strong influence of 
rVSV on early immune responses.22
This finding is of substantial interest since, similarly, rVSV might have the capacity to 
induce sustained responses to glycoproteins from other emerging viruses, such as the Nipah 
or Lassa viruses.23 This sustained persistence of antibody titres is consistent with that 
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observed by Heppner and colleagues3 in US volunteers in a phase 1b study of rVSV-
ZEBOV vaccine at 1 year (last timepoint assessed) after vaccination, but contrasts with a 
study by Khurana and colleagues13 in which rapid antibody decline was reported in 
recipients of two doses of rVSV-ZEBOV vaccine. Our understanding is that the surface 
plasmon resistance assay used by Khurana and colleagues13 in their study of human 
antibodies after VSV-Ebola vaccination essentially detected high levels of IgM antibodies, 
whereas the FANG ELISA assay (used in our study and that of Heppner and colleagues3) 
specifically measures IgG antibodies. The rapid decline of IgM versus the longer persistence 
of IgG antibodies could explain this discrepancy and be consistent with the rapid waning of 
some neutralising antibodies found in our study (appendix).
The influence of rVSV-ZEBOV vaccine is dose dependent. Vaccine doses below 3 million 
pfu, which induce lower cytokine responses,22 led to weaker early (ie, 28 day) antibody 
responses, suggesting weaker induction of short-term plasma cells than might be achieved 
with a higher dose of vaccine.1–3 But this weaker response could just have been a delay in 
response; by 1 year after vaccination, GMCs in the participants in the Lambaréné and 
Geneva groups who were given low doses of vaccine (300 000 pfu) resembled those of 
participants immunised with doses that were ten and 100 times higher, and by 2 years (for 
the Geneva group), GMCs in those given the low dose of vaccine were 1·6-times higher than 
on day 28. Thus, although high doses of vaccine might contribute to early protection, lower 
(less reactogenic1,2,22) doses than these could be attractive should preventive campaigns be 
considered necessary. We postulate that the induction of delayed but ultimately high humoral 
responses by low doses of rVSV-ZEBOV vaccine result from a facilitated escape of the 
vaccine load from lower early antiviral responses,22 enabling longer antigen persistence and 
thus potentially more durable immune responses than those achieved with a higher dose of 
vaccine.
The same mechanism could be true in participants with vaccine-related arthritis. We 
previously reported the onset of vaccine-related arthritis in the second week after 
immunisation in a substantial proportion (24%) of the Geneva group,1,2,16 an observation 
that was less frequent in the Lambaréné and Kilifi groups. Reasons for the discrepancy have 
been explored elsewhere.1,2 The phase 1 rVSV-ZEBOV trial3 in the USA confirmed the 
occurrence of vaccine-related arthritis after immunisation, at an incidence of 5%, with no 
association with race or ethnic origin. Along with the similarities of vaccine plasma 
signatures observed in the Geneva and Lambaréné groups,22 this similarity between studies 
suggests that volunteer perception, ascertainment, and reporting methods could have a role 
in the reported variable incidence of vaccine-related arthritis. In a subsequent study,22 we 
showed that participants who were given high doses of vaccine (ie, ≥10 million pfu) had 
significantly weaker cytokine and chemokine responses than those given low doses of 
vaccine (ie, 300 000 pfu), suggesting weaker initial viral control among the high-dose 
population than the low-dose population. We now show that vaccine-related arthritis is 
associated with significantly higher GMCs, especially in participants given low doses of 
vaccine, than among those who did not get vaccine-related arthritis (figure 3). Participants 
who were given a low dose of vaccine versus those given a high dose, and those given a high 
dose of vaccine with vaccine-related arthritis versus those without vaccine-related arthritis, 
have weaker cytokine and chemokine responses than their respective counterparts.22 
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Therefore, vaccine escape from early innate responses, and thus extended viral persistence, 
could contribute to the onset of rVSV-ZEBOV-related arthritis and result in increased 
antibody responses; therefore, the so-called benefit of extended antigen presentation 
contributes less in people given a high dose of vaccine than in those given a low dose.
Participants in the Lambaréné group had a higher proportion of baseline seropositivity than 
those in the other groups, although none of the participants had had known contacts in 
Gabon’s 2002 outbreak of Ebola virus disease. Repeated antigenic stimulation or aborted 
infection has been postulated to occur through the handling or eating of fruitbats (a common 
source of bushmeat) or fruits contaminated by bat saliva, urine, or faeces containing 
infectious virus, inactivated virus, or viral antigens.24 Therefore, baseline antibodies could 
reflect cross-reactive antibodies to other filoviruses, since baseline seropositivity did not 
influence anti-ZEBOV glycoprotein antibody persistence.
We observed a pattern toward higher ZEBOV glycoprotein-specific IgG titres at 1 year after 
vaccination in female participants than male participants in Geneva. Women are known to 
have more vigorous innate and adaptive responses,25 and stronger responses have 
occasionally been documented in female vaccinees.26 The finding was not, however, 
confirmed by multivariable analyses.
By contrast with the ZEBOV glycoprotein-binding IgG con-centrations, neutralising 
antibody titres of the Geneva group were significantly lower at month 6 than at day 28 for all 
dose groups. This finding differs from the persistence reported at 6 months after vaccination 
by another group using a similar assay to assess the Lambaréné and Kilifi cohorts.1,3 A 
similar reduction of titres had been observed in the Geneva group, Lambaréné group, and 
Kilifi group volunteers using a pseudovirion neutralisation assay,2 but not in US volunteers.
3 This variability highlights the poor correlation among neutralisation assays27 and the need 
for collaborative efforts to validate and standardise assays before conclusions can be reached 
on the persistence of neutralising antibodies and their putative role in protection against 
disease.
Our study has limitations. Not all people who had been vaccinated in the previous studies 
were available for later-phase sampling, but the missing samples are few. The immune 
correlates of protection against Ebola virus disease have not been defined. The role of 
vaccine-induced T cells in protection against Ebola virus is still unknown and their 
assessment was not part of this study protocol. IgM vaccine antibodies were shown to 
contribute to in-vitro virus neutralisation, but over time IgM responses are replaced by IgG 
responses.13 Neutralising antibodies have been assessed only up to 6 months after 
immunisation, pending the availability of validated sensitive assays. Their role in protection 
is still unclear. Participants who were seropositive at baseline were not excluded from the 
analysis, but baseline seropositivity did not affect antibody persistence. If ZEBOV 
glycoprotein-specific IgG mediates protection, the protective concentration remains 
unknown. We addressed this limitation by using low-stringency (seropositivity) and high-
stringency (yearly GMC ratio compared with that at day 28, at which protection had been 
observed) markers. Although a protective threshold would likely rank somewhere in 
between, the use of both markers gave the same conclusion—ie, that the humoral response is 
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durable in the 2 years following so-called one-shot rVSV-ZEBOV vaccination. Given the 
logistical challenges inherent in vaccine campaigns in Ebola-endemic regions, the 
importance of single-injection vaccination goes beyond mere convenience.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in context
Evidence before this study
Since the durability of recombinant vesicular stomatitis virus (rVSV)-Zaire Ebola virus 
(ZEBOV)-induced protection is probably best estimated by antibody persistence in 
people who have been vaccinated, we sought to identify information on this durability 
after single-dose vaccination. We did this by searching the MEDLINE and 
ClinicalTrials.gov databases, with no language restrictions, for studies that were 
published before Sept 1, 2017, using keywords including “Ebola”, “vaccine”, “VSV-
Ebola”, “rVSV-ZEBOV”, “rVSV-EBOV”, “VSV-EBOV”, “durability”, and “long-term 
immunity”. These terms were then combined with the additional terms “antibody 
persistence”, “long-term protection”, “durable immune response”, and “antibody 
response over time” and the search was broadened to include the Google search engine. 
We identified one clinical trial reporting antibody concentrations at 1 year after 
vaccination with rVSV-ZEBOV but found no information on antibody persistence in 
human beings beyond this interval. Antibody persistence in this study, which tested a 
wide range of rVSV-ZEBOV doses in a US population, was remarkably robust, with 1-
year geometric mean concentrations (GMCs) of anti-ZEBOV IgG antibodies in the 
higher dose groups found to not be significantly lower than GMCs at 28 days after 
vaccination.
Added value of this study
This study provides new data on the durability of the humoral immune response up to 2 
years after single-dose injection with rVSV-ZEBOV vaccine in a population of primarily 
European ancestry, and additional data on durability at 1 year after vaccination in two 
African populations.
Implications of all the available evidence
The Wellcome Trust-Center for Infectious Disease Research and Policy Ebola Vaccine 
Team B initiative recommends that any vaccine used for immunisation of contacts of 
patients with Ebola virus disease should induce protection lasting at least 2 years. These 
results suggest that a single injection of rVSV-ZEBOV vaccine is likely to fulfill this 
recommendation, and larger, observational studies after vaccination are needed to 
confirm this hypothesis.
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Figure 1. Trial profile
pfu=plaque-forming units.
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Figure 2. GMCs of ZEBOV-GP-specific antibodies in Geneva (A), Lambaréné (B), and Kilifi (C)
See appendix for GMC ratios and descriptive statistics. Error bars show 95% CI. EU=ELISA 
arbitrary units.
GMCs=geometric mean concentrations. pfu=plaque-forming units. ZEBOV-GP=Zaire Ebola 
virus glycoprotein.
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Figure 3. GMCs of ZEBOV glycoprotein-specific antibodies in the Geneva group with and 
without vaccine-related arthritis by dose group
(A) Low-dose group—ie, 300 000 pfu of vaccine. (B) High-dose group—ie, 10 million or 50 
million pfu of vaccine. p values are for the comparison of dose groups at each timepoint (see 
appendix for a listing of values and descriptive statistics). Error bars show 95% CI. 
GMC=geometric mean concentration. EU=ELISA arbitrary units. pfu=plaque-forming units. 
ZEBOV-GP=Zaire Ebola virus glycoprotein.
Huttner et al. Page 18
Lancet Infect Dis. Author manuscript; available in PMC 2019 March 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Huttner et al. Page 19
Ta
bl
e 
1
D
em
og
ra
ph
ic
, c
lin
ic
al
, a
nd
 im
m
un
ol
og
ic
al
 c
ha
ra
ct
er
ist
ic
s a
t f
o
llo
w
-u
p 
en
ro
lm
en
t (
12
 m
on
th
s a
fte
r i
mm
un
isa
tio
n)
A
ll
G
en
ev
a
 g
ro
u
p
La
m
ba
ré
né
 g
ro
u
p
K
ili
fi 
gr
o
u
p
Lo
w
 d
os
e;
30
0 
00
0 
pf
u
H
ig
h 
do
se
;
10
 m
ill
io
n 
pf
u
H
ig
h 
do
se
;
50
 m
ill
io
n 
pf
u
Lo
w
 d
os
e;
30
0 
00
0 
pf
u
In
te
rm
ed
ia
te
 
do
se
;
3 
m
ill
io
n 
pf
u
H
ig
h 
do
se
;
20
 m
ill
io
n 
pf
u
In
te
rm
ed
ia
te
 
do
se
;
3 
m
ill
io
n 
pf
u
H
ig
h 
do
se
;
20
 m
ill
io
n 
pf
u
G
ro
up
 si
ze
 a
t v
ac
ci
na
tio
n
21
7
 
 
51
 
 
35
 
 
16
 
 
20
 
 
39
 
 
16
 
 
20
 
 
20
G
ro
up
 si
ze
 a
t 1
2 
m
on
th
s
19
7
 
 
49
 
 
32
 
 
14
 
 
15
 
 
36
 
 
12
 
 
20
 
 
19
A
ge
, y
ea
rs
 
 
35
 (1
1)
 
 
40
 (1
1)
 
 
42
 (1
2)
 
 
43
 (1
4)
 
 
29
 (8
)
 
 
28
 (8
)
 
 
25
 (5
)
 
 
34
 (7
)
 
 
32
 (7
)
Se
x
 
 
 
Fe
m
al
e
 
 
63
 (3
2%
)
 
 
26
 (5
3%
)
 
 
14
 (4
4%
)
 
 
 
 
4 
(29
%)
 
 
 
 
5 
(31
%)
 
 
 
 
3 
(9%
)
 
 
 
 
1 
(6%
)
 
 
 
 
6 
(30
%)
 
 
 
 
4 
(21
%)
 
 
 
M
al
e
13
4 
(68
%)
 
 
23
 (4
7%
)
 
 
18
 (5
6%
)
 
 
10
 (7
1%
)
 
 
10
 (6
7%
)
 
 
33
 (9
2%
)
 
 
11
 (9
2%
)
 
 
14
 (7
0%
)
 
 
15
 (7
9%
)
Et
hn
ic
 o
rig
in
 
 
 
B
la
ck
10
0 
(51
%)
 
 
 
 
0
 
 
 
 
1 
(3%
)
 
 
 
 
0
 
 
16
 (1
00
%)
 
 
35
 (1
00
%)
 
 
12
 (1
00
%)
 
 
17
 (8
5%
)
 
 
19
 (1
00
%)
 
 
 
W
hi
te
 
 
92
 (4
7%
)
 
 
49
 (1
00
%)
 
 
26
 (8
1%
)
 
 
14
 (1
00
%)
 
 
 
 
0
 
 
 
 
0
 
 
 
 
0
 
 
 
 
3 
(15
%)
 
 
 
 
0
 
 
 
O
th
er
 
 
 
 
5 
(3%
)
 
 
 
 
0
 
 
 
 
5 
(16
%)
 
 
 
 
0
 
 
 
 
0
 
 
 
 
0
 
 
 
 
0
 
 
 
 
0
 
 
 
 
0
Cl
in
ic
al
 c
ha
ra
ct
er
ist
ic
s
 
 
 
Va
cc
in
e-
re
la
te
d 
ar
th
rit
is
 
 
24
 (1
2%
)
 
 
12
 (2
4%
)
 
 
 
 
8 
(25
%)
 
 
 
 
3 
(21
%)
 
 
 
 
0
 
 
 
 
0
 
 
 
 
0
 
 
 
 
1 
(5%
)
 
 
 
 
0
Im
m
un
ol
og
ic
al
 c
ha
ra
ct
er
ist
ic
s
 
 
 
Se
ro
po
sit
iv
ity
 b
ef
or
e 
va
cc
in
at
io
n*
 
 
18
 (9
%)
 
 
 
 
1 
(2%
)
 
 
 
 
1 
(3%
)
 
 
 
 
1 
(7%
)
 
 
 
 
2 
(13
%)
 
 
 
 
7 
(20
%)
 
 
 
 
5 
(42
%)
 
 
 
 
1 
(5%
)
 
 
 
 
0
 
 
 
Se
ro
po
sit
iv
ity
 a
t d
ay
 2
8
18
4 
(94
%)
†
 
 
39
 (8
0%
)
 
 
32
 (1
00
%)
 
 
13
 (1
00
%)
†
 
 
13
 (8
7%
)
 
 
36
 (1
00
%)
 
 
12
 (1
00
%)
 
 
20
 (1
00
%)
 
 
19
 (1
00
%)
D
at
a 
ar
e 
n,
 n
 (%
), o
r m
ea
n (
SD
). P
erc
en
tag
es 
ha
v
e 
be
en
 c
al
cu
la
te
d 
w
ith
 th
e 
gr
ou
p 
siz
e 
at
 1
2 
m
on
th
s a
s t
he
 d
en
om
in
at
or
.
 
pf
u=
pl
aq
ue
-fo
rm
in
g 
un
its
.
*
Se
ro
po
sit
iv
ity
 w
as
 e
x
pe
rim
en
ta
lly
 d
ef
in
ed
 b
y 
a 
Za
ire
 E
bo
la
 v
iru
s g
ly
co
pr
ot
ei
n-
sp
ec
ifi
c 
Ig
G
 a
nt
ib
od
y 
tit
re
 ≥
58
·8
4 
EU
/m
L.
† O
ne
 sa
m
pl
e 
fo
r d
ay
 2
8 
se
ro
po
sit
iv
ity
 w
as
 m
iss
in
g.
Lancet Infect Dis. Author manuscript; available in PMC 2019 March 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Huttner et al. Page 20
Ta
bl
e 
2
G
M
C
s o
f Z
EB
O
V
 g
ly
co
pr
o
te
in
-s
pe
ci
fic
 a
nt
ib
od
ie
s a
cr
o
ss
 d
os
es
 a
nd
 st
ud
ie
s a
t d
iff
er
en
t t
im
ep
oi
nt
s
D
ay
 0
D
ay
 2
8
D
ay
 5
6
D
ay
 8
4
M
on
th
 6
Ye
a
r 
1
Ye
a
r 
2
n
G
M
C
, E
U
/m
L
n
G
M
C
, E
U
/m
L
n
G
M
C
, E
U
/m
L
n
G
M
C
, E
U
/m
L
n
G
M
C
, E
U
/m
L
n
G
M
C
, E
U
/m
L
n
G
M
C
, E
U
/m
L
G
en
ev
a
 g
ro
u
p
30
0 
00
0 
pf
u
51
 
30
·0
(28
·9–
31
·1;
 p=
0·1
9*
)
51
 
 
 
26
7·
4
(17
5·3
–4
07
·9;
 p<
0·0
01
*
)
N
D
N
D
50
 
 
 
82
4·
9
(57
6·7
–1
17
9·9
; p
=0
·00
6*
)
51
 
 
 
58
3·
9
(40
7·5
–8
36
·5;
 p=
0·1
9*
)
49
 
 
 
61
8·
2
(41
2·0
–9
27
·6;
 p=
0·0
4*
)
45
44
0·
8
(29
7·8
–6
52
·5;
 p=
0·0
3*
)
10
 m
ill
io
n 
pf
u
35
 
32
·6
(28
·2–
37
·7)
34
 
 
 
82
1·
2
(57
9·7
–1
16
3·5
)
N
D
N
D
33
 
13
32
·1
(95
5·9
–1
85
6·5
)
34
 
 
 
74
7·
6
(53
9·1
–1
03
6·9
)
32
 
10
05
·7
(69
7·4
–1
45
0·4
)
31
76
1·
3
(51
6·2
–1
12
2·8
)
50
 m
ill
io
n 
pf
u
16
 
31
·9
(28
·4–
36
·0;
 p=
0·8
6†
)
14
 
13
83
·0
(99
6·0
–1
92
0·4
; p
=0
·09
† )
N
D
N
D
16
 
19
93
·7
(15
47
·9–
25
67
·8;
 p=
0·1
0†
)
15
 
 
 
86
5·
7
(63
0·6
–1
18
8·6
; p
=0
·06
† )
14
 
10
37
·9
(80
4·2
–1
33
9·6
; p
=0
·90
† )
14
70
7·
8
(54
6·6
–9
16
·4;
 p=
0·7
8†
)
10
 o
r
50
 m
ill
io
n 
pf
u
51
 
32
·4
(28
·2–
37
)
48
 
 
 
95
6·
1
(68
0·1
–1
34
4·0
)
N
D
N
D
49
 
15
91
·6
(11
18
·6–
20
64
·3)
49
 
 
 
78
2·
6
(52
1·7
–1
06
9·6
)
46
 
10
15
·4
(73
2·7
–1
40
7·1
)
45
74
4·
3
(52
8·2
–1
04
8·6
)
La
m
ba
ré
né
 g
ro
u
p
30
0 
00
0 
pf
u
19
 
33
·7
(27
·6–
41
·1;
 p=
0·0
2‡
)
20
 
 
 
54
0·
2
(25
4·4
–1
14
6·7
; p
=0
·04
‡ )
17
 
 
 
80
9·
9
(35
5·3
–1
84
6·1
; p
=0
·02
‡ )
17
 
 
 
65
4·
0
(33
3·1
–1
28
3·9
; p
=0
·02
‡ )
16
 
 
 
37
5·
2
(18
9·9
–7
41
·2;
 p<
0·0
01
‡ )
15
 
 
 
60
2·
3
(35
7·9
–1
01
3·7
; p
=0
·06
‡ )
N
D
N
D
3 
m
ill
io
n 
pf
u
39
 
40
·6
(29
·2–
56
·5)
39
 
12
45
·0
(77
8·4
–1
99
1·2
)
37
 
13
30
·7
(82
9·7
–2
13
4·1
)
35
 
 
 
99
4·
0
(62
9·0
–1
57
1·0
)
37
 
 
 
68
4·
6
(47
9·6
–9
77
·2)
36
 
 
 
61
6·
1
(44
1·3
–8
60
·1)
N
D
N
D
20
 m
ill
io
n 
pf
u
16
 
69
·1
(39
·7–
12
0·2
)
16
 
15
03
·0
(94
3·6
–2
39
4·0
)
13
 
25
89
·5
(16
25
·2–
41
26
·0)
14
 
18
25
·7
(11
33
·6–
29
40
·2)
15
 
15
14
·4
(97
2·1
–2
35
9·3
)
12
 
14
33
·3
(57
1·8
–3
59
2·7
)
N
D
N
D
K
ili
fi 
gr
o
u
p
3 
m
ill
io
n 
pf
u
20
 
34
·0
(25
·1–
46
·2;
 p=
0·3
3§
)
20
 
10
05
·2
(65
5·2
–1
54
2·1
; p
=0
·34
§ )
20
 
10
54
·9
(72
1·6
–1
54
2·3
; p
=0
·68
§ )
20
 
10
18
·9
(71
1·0
–1
46
0·2
; p
=0
·75
§ )
20
 
 
 
75
6·
9
(52
0·1
–1
10
1·5
; p
=0
·54
§ )
20
 
 
 
66
7·
9
(48
4·7
–9
20
·2;
 p=
0·0
4§
)
N
D
N
D
20
 m
ill
io
n 
pf
u
18
 
29
·4
(29
·4–
29
·4)
20
 
 
 
78
5·
3
(57
1·8
–1
07
8·7
)
20
 
 
 
94
4·
6
(62
5·8
–1
42
5·7
)
20
 
 
 
94
6·
8
(69
5·5
–1
28
8·9
)
20
 
 
 
87
7·
9
(62
5·7
–1
23
1·9
)
19
 
10
83
·1
(76
6·8
–1
52
9·8
)
N
D
N
D
D
at
a 
ar
e 
G
M
C 
(95
% 
CI
; p
 va
lu
e) 
or 
GM
C 
(95
% 
CI
); 
n i
s n
um
be
r o
f s
am
ple
s a
v
ai
la
bl
e 
at
 ti
m
ep
oi
nt
. G
M
C=
ge
om
et
ric
 m
ea
n 
co
nc
en
tra
tio
n.
 E
U
=E
LI
SA
 a
rb
itr
ar
y 
un
its
. Z
EB
OV
=Z
ai
re
 E
bo
la
 v
iru
s. 
pf
u=
pl
aq
ue
-fo
rm
in
g 
un
its
. N
D
=n
ot
 d
on
e.
*
Co
m
pa
ris
on
 o
f G
M
Cs
 b
et
w
ee
n 
pa
rti
ci
pa
nt
s w
ho
 w
er
e 
gi
v
en
 a
 lo
w
 d
os
e 
(30
0 0
00
 pf
u) 
an
d t
ho
se 
wh
o w
ere
 gi
v
en
 a
 h
ig
h 
do
se
 (1
0 m
illi
on
 or
 50
 m
illi
on
 pf
u) 
of 
va
cc
in
e.
† C
om
pa
ris
on
 o
f G
M
Cs
 b
et
w
ee
n 
pa
rti
ci
pa
nt
s w
ho
 w
er
e 
gi
v
en
 1
0 
m
ill
io
n 
an
d 
50
 m
ill
io
n 
pf
u 
of
 v
ac
ci
ne
 in
 th
e 
G
en
ev
a 
st
ud
y.
‡ C
om
pa
ris
on
 o
f G
M
Cs
 b
et
w
ee
n 
pa
rti
ci
pa
nt
s w
ho
 w
er
e 
gi
v
en
 3
00
 0
00
 a
nd
 2
0 
m
ill
io
n 
pf
u 
of
 v
ac
ci
ne
 in
 th
e 
La
m
ba
ré
né
 st
ud
y.
§ C
om
pa
ris
on
 o
f G
M
Cs
 b
et
w
ee
n 
pa
rti
ci
pa
nt
s w
ho
 w
er
e 
gi
v
en
 3
 m
ill
io
n 
an
d 
20
 m
ill
io
n 
pf
u 
of
 v
ac
cc
in
e 
in
 th
e 
K
ili
fi 
stu
dy
.
Lancet Infect Dis. Author manuscript; available in PMC 2019 March 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Huttner et al. Page 21
Table 3
Multivariable linear regression model with mixed effects assessing determinants of GMC 
ratios by dose of vaccine and study group
Low dose* Intermediate dose† High dose‡
Ratio of GMC (95% CI) p value Ratio of GMC (95% CI) p value Ratio of GMC (95% CI) p value
Geneva group
Days since vaccination
    84 1·44 (1·15–1·79) 0·0016 NA     ·· 1·81 (1·51–2·17) <0·0001
    168 1 (ref)   ·· NA     ·· 1 (ref)     ··
    365 1·05 (0·84–1·31) 0·65 NA     ·· 1·23 (1·03–1·48)   0·026
    730 0·65 (0·51–0·81) 0·0003 NA     ·· 0·91 (0·76–1·09)   0·32
Sex
    Male 1 (ref)   ··   ··     ·· 1 (ref)     ··
    Female 1·53 (0·80–2·91) 0·20 NA     ·· 1·46 (0·91–2·35)   0·12
Baseline seropositivity
    No 1 (ref)   ··   ··     ·· 1 (ref)     ··
    Yes 2·18 (0·22–21·80) 0·51 NA     ·· 2·18 (0·82–5·79)   0·12
Age, per 10 years 1·30 (0·96–1·76) 0·096 NA     ·· 1·12 (0·92–1·36) 0·26
Vaccine-related arthritis
    No 1 (ref)   ··     ·· 1 (ref)
    Yes 1·98 (0·90–4·38) 0·096 NA     ·· 1·39 (0·79–2·43)   0·26
Lambaréné group
Days since vaccination
    56 1·81 (1·25–2·62) 0·0031 1·79 (1·51–2·12) <0·0001 1·70 (1·07–2·69)   0·030
    84 1·62 (1·12–2·33) 0·013 1·37 (1·15–1·63)   0·0007 1·16 (0·74–1·81)   0·52
    168 1 (ref)   ·· 1 (ref)     ·· 1 (ref)     ··
    365 1·16 (0·78–1·73) 0·45 0·89 (0·75–1·05)   0·18 1·20 (0·73–1·95)   0·48
Sex
    Male 1 (ref)   ·· 1 (ref)     ·· 1 (ref)     ··
    Female 3·16 (0·84–11·81) 0·11 1·06 (0·47–2·41)   0·89 0·19 (0·02–2·26)   0·20
Baseline seropositivity
    No 1 (ref)   ·· 1 (ref)     ·· 1 (ref)     ··
    Yes 3·08 (0·49–19·27) 0·25 1·42 (0·75–2·70)   0·29 1·19 (0·45–3·17)   0·73
Age, per 10 years 0·58 (0·25–1·35) 0·22 0·99 (0·69–1·42)   0·95 0·86 (0·35–2·13)   0·75
Kilifi group
Days since vaccination
    60 NA   ·· 1·39 (1·07–1·81)   0·014 1·08 (0·83–1·40)   0·58
    90 NA   ·· 1·35 (1·04–1·75)   0·027 1·08 (0·83–1·40)   0·57
    180 NA   ·· 1 (ref)     ·· 1 (ref)     ··
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Low dose* Intermediate dose† High dose‡
Ratio of GMC (95% CI) p value Ratio of GMC (95% CI) p value Ratio of GMC (95% CI) p value
    365 NA   ·· 0·88 (0·68–1·15)   0·35 1·14 (0·88–1·49)   0·32
Sex
    Male NA   ·· 1 (ref)     ·· 1 (ref)     ··
    Female NA   ·· 0·68 (0·35–1·32)   0·27 1·49 (0·69–3·21)   0·32
Baseline seropositivity
    No NA   ·· 1 (ref)     ·· NA     ··
    Yes NA   ·· 1·17 (0·28–4·80)   0·83 NA     ··
Age, per 10 years NA   ·· 0·89 (0·59–1·35)   0·60 1·04 (0·67–1·60)   0·88
Log10 ELISA values were modelled and regression coefficients were back-transformed to express results as ratio of GMC. The model includes a 
random intercept (for variability between participants), excludes placebo recipients and day 0 and 28 titres, and is adjusted for sex, age, and 
baseline seropositivity. Unless specified otherwise (days since vaccination), this models GMC at 1 year after immunisation. GMC=geometric mean 
concentration. NA=not applicable. pfu=plaque-forming units.
*300 000 pfu.
†3 million pfu.
‡10 million or 50 million pfu in Geneva group and 20 million pfu in Lambaréné and Kilifi groups.
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